Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or ...

Financial Data and Key Metrics Changes - Prescription product net revenue for the year ended December 31, 2022, was approximately $11.9 million, an increase of 178.7% compared to approximately $4.3 million for the year ended December 31, 2021 [7][52] - The loss from operations decreased from $40.7 million in 2021 to $34.4 million in 2022, largely due to an improvement in net revenue and decreased costs [24] - Non-GAAP EBITDA showed a net loss of $28.1 million in 2022, compared to a net loss of $37.5 million in 2021 [54] Business Line Data and Key Metrics Changes - Mytesi total prescription volume was approximately 5,947 in 2022, with a slight decrease of about 2% in Q4 2022 compared to Q3 2022 [23][53] - Canalevia-CA1 net revenue was approximately $24,000 in Q4 2022, representing a 100% increase over Q3 2022 [58] Market Data and Key Metrics Changes - The gross to net discount for Mytesi was approximately 20% in 2022, with the transition to specialty pharmacy distribution aiding in the preparation for potential future indication expansions [76] - The global market for chemotherapy-induced nausea and vomiting is projected to reach $3.9 billion by 2029, indicating a significant opportunity for Crofelemer in the CTD market [43] Company Strategy and Development Direction - The company is focused on expanding the approved indication of Mytesi from HIV-related diarrhea to include chemotherapy therapy-related diarrhea (CTD) [39] - Plans include supporting proof-of-concept studies for Crofelemer in patients with short bowel syndrome (SBS) and microvillous inclusion disease (MVID) [16][49] - The company aims to leverage AI technology to improve patient access to Mytesi and reduce reimbursement barriers [28][77] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the transformative potential of key clinical milestones expected in 2023, which could enhance value recognition for the company [30][36] - The company highlighted the importance of addressing the unmet medical need for CTD, as many patients discontinue life-saving cancer therapies due to diarrhea [40] Other Important Information - The company had cash of approximately $15.3 million as of March 24, 2023, which is crucial for achieving clinical milestones [21][37] - The transition to a limited distribution network of specialty pharmacies has resulted in reduced distribution costs and a higher average net price for Mytesi [56] Q&A Session Summary Question: Is the primary completion date still this month, March 2023, for chemotherapy-induced diarrhea? - Management confirmed that enrollment is expected to complete early in the second quarter of 2023, with the primary endpoint targeted for the third quarter [80] Question: Are you planning any cash raises to support your trials this year? - Management indicated that significant expenses are associated with clinical work to expand indications, but cost savings have been realized from distribution changes [82] Question: Does Crofelemer also work on IBS? - Management noted that there is published Phase II data for IBS with Crofelemer, but current focus remains on CTD, SBS, and MVID [90]

Financial Position - As of December 31, 2022, Jaguar Health reported total assets of $47.452 million, a decrease from $53.265 million in 2021[535]. - The company had an accumulated deficit of $266.948 million as of December 31, 2022, compared to $219.494 million in 2021, indicating increasing financial losses[535]. - Total current liabilities increased significantly to $30.339 million in 2022 from $15.471 million in 2021, reflecting a rise in financial obligations[535]. - Cash reserves decreased to $5.469 million in 2022 from $17.051 million in 2021, highlighting liquidity challenges[535]. - Jaguar Health's total liabilities increased to $48.808 million in 2022 from $41.412 million in 2021, indicating a growing debt burden[535]. - The company expects continuing future losses, raising substantial doubt about its ability to continue as a going concern[522]. - The company had a noncontrolling interest of $(699) thousand in 2022, down from $242 thousand in 2021, indicating a decline in minority interests[535]. Revenue and Growth - Product revenue for the year ended December 31, 2022, was $11,956,000, a significant increase from $4,335,000 in 2021, representing a growth of 176%[537]. - Net revenues from the sale of Mytesi were $11.7 million for the year ended December 31, 2022, compared to $4.3 million for 2021, representing a 172% increase[605]. - Canalevia-CA1 product revenues were $167,000 for the year ended December 31, 2022, compared to zero for 2021, indicating a successful market entry[606]. - Neonorm revenues were $48,000 for the year ended December 31, 2022, down from $62,000 in 2021, reflecting a 23% decrease[606]. - Revenue from Mytesi sales in 2022 was primarily derived from three major pharmaceutical distributors, with Customer 2 contributing 35% and Customer 3 contributing 53% of total revenue[569]. Expenses and Losses - Total operating expenses increased to $46,371,000 in 2022 from $45,043,000 in 2021, reflecting a rise of 3%[537]. - The net loss for the year ended December 31, 2022, was $48,395,000, an improvement compared to a net loss of $52,600,000 in 2021, indicating a reduction of approximately 8%[541]. - The net loss per share, basic and diluted, improved to $36.18 in 2022 from $88.22 in 2021[537]. - Research and development expenses rose to $17,647,000 in 2022, up from $15,079,000 in 2021, marking an increase of 17%[537]. - Comprehensive loss for the year ended December 31, 2022, was $49,075,000, compared to $52,600,000 in 2021, showing a decrease of approximately 7%[541]. - The company did not incur any income tax expense for both years reported[537]. Cash Flow and Financing - Total cash used in operating activities for 2022 was $33,104,000, slightly better than $34,970,000 in 2021, indicating a 5% reduction in cash burn[546]. - Cash provided by financing activities in 2022 amounted to $23,181,000, a significant decrease from $43,937,000 in 2021, reflecting a 47% decline[546]. - The company has an immediate need to raise cash, as current cash balances are insufficient to fund operations for the next year[560]. - Cash at the end of 2022 was $5,469,000, down from $17,051,000 at the beginning of the year, indicating a cash decrease of 68%[546]. Assets and Liabilities - Intangible assets, net, were reported at $22.439 million as of December 31, 2022, slightly down from $22.651 million in 2021[535]. - The company did not recognize any impairment loss for intangible assets in the financial statements for the year ended December 31, 2022[527]. - The Company’s amortization expense for intangible assets was $1.8 million in 2022, with total intangible assets net of amortization at $22.439 million[678]. - Total inventory increased to $7.024 million in 2022 from $4.900 million in 2021, with significant increases in raw materials and work in process[675]. - Notes payable increased to $47.255 million in 2022 from $45.503 million in 2021, with a net note payable of $33.627 million after discounts[681]. Agreements and Commitments - The Company entered into a 15-year License Agreement with Knight Therapeutics for exclusive commercialization rights of Jaguar human health products in Canada and Israel, with potential payments of up to $18 million based on regulatory and sales milestones[615]. - The Company entered into a manufacturing and supply agreement with Glenmark Life Sciences for the production of crofelemer, effective until March 31, 2023[667]. - The Company has a commitment to purchase a minimum of 500 kilograms of crofelemer per year from Glenmark, with a remaining commitment of 125 kilograms as of December 31, 2022[668]. - The Company entered into a royalty interest purchase agreement, selling a $12.0 million royalty interest for an aggregate purchase price of $6.0 million[683]. - The Company is obligated to make minimum royalty payments starting at $250,000, increasing to $750,000 over time, based on the terms of the March 2021 Purchase Agreement[708]. Other Financial Metrics - The fair value of the Streeterville Note was $7.8 million as of December 31, 2021, and $6.0 million at issuance on January 13, 2021[642]. - The fair value of the Level 3 liability for the Streeterville Note increased by $21, resulting in an ending fair value of $7.839 million as of December 31, 2022[640]. - The discount rate for the royalty interest under the December 2020 Purchase Agreement was initially set at 23.70% and adjusted to 29.55% as of December 31, 2022 due to changes in forecasted future revenues[703]. - The fair value measurement for Level 3 inputs showed a risk-adjusted discount rate range of 11.53%-26.06% in 2022, compared to 6.78%-21.31% in 2021[644]. - The Company experienced a cumulative loss of $2.2 million due to the extinguishment of certain royalty interests[693].

Jaguar Health Inc. (NASDAQ:JAGX) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Lisa Conte - President, Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, I’d like to remind you that management may make forward-looking statements relating to the matters as contained growth prospects for the company. Uncertainties regarding market acceptance of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (Stat ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q2 2022 Earnings Conference Call August 22, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President, and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market ac ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or ...

Jaguar Health, Inc. (NASDAQ: JAGX) Overview – June 2022 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. ("Jaguar" or the "Company") and Napo Therapeutics S.p.A. ("Napo Therapeutics", formerly known as "Napo EU") to develop and commercialize crofelemer in Europe (excluding Russia) for HIV-related diarrhea, short bowel syndrome a ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Peter Hodge - Senior Director of IR, Business Development and Special Events Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that the -- that management may make forward-looking statements relating to such mat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...